| Literature DB >> 25002116 |
Eugene Y Kim1, Jamie L Sturgill2, Nitai C Hait1, Dorit Avni1, Evelyn C Valencia1, Michael Maceyka1, Santiago Lima1, Jeremy Allegood1, Wei-Ching Huang1, Shijun Zhang3, Sheldon Milstien1, Daniel Conrad2, Sarah Spiegel4.
Abstract
The tumor necrosis factor (TNF) receptor family member CD40 plays an essential role in the activation of antigen-presenting cells, B cell maturation, and immunoglobulin (Ig) class switching critical for adaptive immunity. Although the bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) and the kinase that produces it, sphingosine kinase 1 (SphK1), have long been implicated in the actions of TNF mediated by engagement of TNFR1, nothing is yet known of their role in CD40-mediated events. We have now found that ligation of CD40 activates and translocates SphK1 to the plasma membrane, leading to generation of S1P. SphK1 inhibition in human tonsil B cells, as well as inhibition or deletion of SphK1 in mouse splenic B cells, significantly reduced CD40-mediated Ig class switching and plasma cell differentiation ex vivo. Optimal activation of downstream CD40 signaling pathways, including NF-κB, p38, and JNK, also required SphK1. In mice treated with a SphK1 inhibitor or in SphK1(-/-) mice, isotype switching to antigen-specific IgE was decreased in vivo by 70 and 55%, respectively. Our results indicate that SphK1 is important for CD40-mediated B cell activation and regulation of humoral responses and suggest that targeting SphK1 might be a useful therapeutic approach to control antigen-specific IgE production. © FASEB.Entities:
Keywords: B cells; NF-κB; inflammation; sphingolipids
Mesh:
Substances:
Year: 2014 PMID: 25002116 PMCID: PMC4202100 DOI: 10.1096/fj.14-251611
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191